NUCANA PLC-ADR (NCNA) Stock Price & Overview
NASDAQ:NCNA • US67022C3043
Current stock price
The current stock price of NCNA is 2.16 USD. Today NCNA is down by -5.68%. In the past month the price increased by 38.79%. In the past year, price decreased by -99.99%.
NCNA Key Statistics
- Market Cap
- 824.29M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.56
- Dividend Yield
- N/A
NCNA Stock Performance
NCNA Stock Chart
NCNA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NCNA. When comparing the yearly performance of all stocks, NCNA is a bad performer in the overall market: 97.72% of all stocks are doing better.
NCNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NCNA. NCNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NCNA Earnings
NCNA Forecast & Estimates
NCNA Groups
Sector & Classification
NCNA Financial Highlights
Over the last trailing twelve months NCNA reported a non-GAAP Earnings per Share(EPS) of -1.56. The EPS increased by 99.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -98.39% | ||
| ROE | -120.66% | ||
| Debt/Equity | 0.03 |
NCNA Ownership
NCNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 360.314B | ||
| AMGN | AMGEN INC | 15.1 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.53 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NCNA
Company Profile
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Company Info
IPO: 2017-09-28
NUCANA PLC-ADR
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT GB
CEO: Hugh Griffith
Employees: 11
Phone: 4401313571111
NUCANA PLC-ADR / NCNA FAQ
What does NUCANA PLC-ADR do?
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
What is the stock price of NUCANA PLC-ADR today?
The current stock price of NCNA is 2.16 USD. The price decreased by -5.68% in the last trading session.
Does NCNA stock pay dividends?
NCNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of NCNA stock?
NCNA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is NUCANA PLC-ADR worth?
NUCANA PLC-ADR (NCNA) has a market capitalization of 824.29M USD. This makes NCNA a Small Cap stock.
Can you provide the upcoming earnings date for NUCANA PLC-ADR?
NUCANA PLC-ADR (NCNA) will report earnings on 2026-06-01.